

1 **Mycobacterial DnaQ is an Alternative Proofreader**

2 **Ensuring DNA Replication Fidelity**

3

4 Ming-Zhi Deng^{1,8}, Qingyun Liu^{2,8}, Shu-Jun Cui^{1,3}, Han Fu^{1,4,5}, Mingyu Gan⁶, Yuan-Yuan Xu¹,
5 Xia Cai¹, Wei Sha⁷, Guo-Ping Zhao^{3,4,5}, Sarah M. Fortune², Liang-Dong Lyu^{1,7,*}

6

7 ¹Key Laboratory of Medical Molecular Virology of the Ministry of Education/Ministry of Health
8 (MOE/NHC), School of Basic Medical Sciences, Fudan University, Shanghai 200032, P.R.China

9 ²Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health,
10 Boston, MA 02115.

11 ³Department of Microbiology and Microbial Engineering, School of Life Sciences, Fudan University,
12 Shanghai, 200433, P.R.China.

13 ⁴CAS Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences,
14 Chinese Academy of Sciences (CAS), Shanghai 200032, P.R.China

15 ⁵University of Chinese Academy of Sciences, Beijing 100049, P.R.China

16 ⁶Center for Molecular Medicine, Children's Hospital of Fudan University, National Children's Medical
17 Center, Shanghai, 201102, P.R.China

18 ⁷Shanghai Clinical Research Center for Tuberculosis, Shanghai Key Laboratory of Tuberculosis,
19 Shanghai Pulmonary Hospital, Shanghai 200433, P.R.China

20 ⁸These authors contributed equally.

21 ***Correspondence should be addressed to L.-D. L. (ld.lyu@fudan.edu.cn)**

22

23 **Abstract**

24 Remove of mis-incorporated nucleotides ensures replicative fidelity. Although the ϵ -exonuclease
25 DnaQ is a well-established proofreader in the model organism *Escherichia coli*, proofreading in
26 mycobacteria relies on the polymerase and histidinol phosphatase (PHP) domain of replicative
27 polymerase despite the presence of an alternative DnaQ homolog. Here, we show that depletion of
28 DnaQ in *Mycobacterium smegmatis* results in increased mutation rate, leading to AT-biased
29 mutagenesis and elevated insertions/deletions in homopolymer tract. We demonstrated that
30 mycobacterial DnaQ binds to the β -clamp and functions synergistically with the PHP domain to
31 correct replication errors. Further, we found that the mycobacterial DnaQ sustains replicative fidelity
32 upon chromosome topological stress. Intriguingly, we showed that a naturally evolved DnaQ variant
33 prevalent in clinical *Mycobacterium tuberculosis* isolates enables hypermutability and is associated
34 with extensive drug resistance. These results collectively establish that the alternative DnaQ
35 functions in proofreading, and thus reveal that mycobacteria deploy two proofreaders to maintain
36 replicative fidelity.

37

38 **Introduction**

39 The emergence of drug-resistant *Mycobacterium tuberculosis* (*Mtb*) poses a great challenge to the
40 global control of tuberculosis, which kills 1.5 million people annually¹. Unlike many other bacteria, in
41 which the development of drug resistance is typically driven by horizontal gene transfer (HGT),
42 genome rearrangement and mutation, all drug resistances characterized in *Mtb* are the result of
43 chromosomal mutations, indicating that the mutational capacity of *Mtb* is one of the key mechanisms
44 underpinning its *de novo* generation of drug resistance^{2,3}.

45 Nucleotide mispairing occurred during DNA replication is a major source of mutagenesis. In the
46 model organism *Escherichia coli*, the fidelity of DNA replication is ensured by the base selection via
47 DNA polymerase α subunit (DnaE), the proofreading by the ϵ subunit 3'-5' exonuclease (DnaQ) and
48 the post-replicative mismatch repair (MMR) committed by a separate enzyme system (MutHLS)³⁻⁵.
49 Proofreading functions as a double-checking point that removes the mis-incorporated nucleotide via
50 3'-5' exonuclease activity⁶. In *E. coli*, the naturally occurred mutants defective in proofreading activity
51 can give rise to 100- to 1000-fold increase of mutation rate and can accelerate the evolving of drug
52 resistance^{7,8}. In addition, deletion of *E. coli dnaQ* also results in growth defect, insufficient
53 polymerization capacity and constitutive SOS phenotype^{6,9,10}.

54 The *E. coli* DnaQ is a single-domain protein containing a DEDDh-family exonuclease domain
55 followed immediately by a clamp-binding motif (CBM)¹¹. Mycobacteria encode two DnaQ homologs
56 which share considerable similarity to the *E. coli* DnaQ in their N-terminal exonuclease domain but
57 generally differ in size and domain organization as a whole (**Supplementary Fig. 1**). The annotated
58 DnaQ contains an extra C-terminal domain of 86 residues homologous to the human breast cancer
59 suppressor protein C-terminal domain (BRCT), which functions as a protein-protein interaction
60 module found in large variety of proteins involved in DNA replication, repair, and recombination¹².
61 The second potential DnaQ homolog (annotated as a hypothetical protein) has a larger C-terminal
62 region of ~400 residues which exhibits high similarity to the endonuclease domain of the nucleotide
63 excision repair protein UvrC. However, despite the *de facto* exonuclease activity of *Mtb* DnaQ *in*
64 *vitro*, previous fluctuation analysis results showed that deletion of the annotated *dnaQ* (*Rv3711c*) in
65 *Mtb* or deletion of both two *dnaQ* homolog genes (*Ms6275* and *Ms4259*) in *Mycobacterium*
66 *smegmatis* (*Msm*) did not lead to the “expected” mutator phenotype¹¹. This functional departure from
67 that of the *E. coli* DnaQ led to the identification of a novel proofreading activity mediated by the
68 polymerase and histidinol phosphatase (PHP) domain of the *dnaE1*-encoded replicative polymerase.
69 Together, these findings demonstrate that the mycobacterial DnaQ is an alternative exonuclease
70 that is structurally and functionally distinct from the *E. coli* DnaQ.

71 Phylogenetic and structural analyses suggested that the PHP domain is the most common
72 replicative exonuclease in the bacterial kingdom^{11,13,14}. Intriguingly, although the presence of active
73 PHP domain appears to be mutually exclusive with the presence of an *E. coli*-like ϵ -exonuclease
74 (DnaQ), it extensively co-exists with the alternative DnaQ¹¹. However, the biological function of this

75 kind of alternative exonuclease remains unclear¹⁵. Here, we show that the mycobacterial DnaQ
76 functions in proofreading and exhibits additional role in maintenance of genomic GC content and
77 correcting of replication errors upon chromosome topological stress. Using the mutation
78 accumulation (MA) assay combined with whole genome sequencing, we demonstrated that deletion
79 of *dnaQ* results in 2.4-fold increase of spontaneous mutation rate in *Msm*, leading to a mutational
80 bias for AT and increased insertions/deletions in homopolymer tract. We demonstrate that
81 mycobacterial DnaQ functions synergistically with PHP domain-mediated proofreading and
82 physiologically associates with the β -clamp. Moreover, loss of *dnaQ* results in replication fork
83 dysfunction upon topological stress, leading to attenuated growth and increased mutagenesis.
84 Importantly, through analyzing the sequence polymorphism from 51,229 *Mtb* clinical isolates, we
85 provide real-world evidence that *dnaQ* was subjected to positive selection in some sublineages and
86 had functional effect on mutagenesis. Particularly, we show that a naturally evolved DnaQ variant
87 prevalent in lineage 4.3 (16.5%) enables *Mtb* hypermutability and is associated with extensive drug
88 resistance, suggesting that the mutator-like evolution trajectory may exist during *Mtb*'s adaptation.
89 These findings collectively establish that mycobacterial DnaQ is an alternative proofreader and
90 provide a new action model of DNA replication proofreading deploying two proofreaders (PHP and
91 DnaQ), which may have broad implication with respect to DNA metabolism.

92

93 **Results**

94 **Deletion of *dnaQ* results in increased mutation rate in *Msm***

95 To investigate whether mycobacterial *dnaQ* contributes to the maintenance of DNA replication fidelity,
96 we constructed the null mutant strain Δ *dnaQ*, Δ *Ms4259* (which encodes the second potential *dnaQ*
97 homolog) and Δ *dnaQ* Δ *Ms4259* in *Msm* and estimated the mutation rate by fluctuation analysis
98 (**Fig.S2A**). Deletion of these genes did not affect bacterial growth in vitro (**Fig.S2B**). Consistent with
99 previous study¹¹, our results showed that these mutant strains did not exhibit significant increase of
100 spontaneous mutation rate (defined by non-overlapping 95% confidence intervals [CI]) (**Fig. 1A** and
101 **Table S1**). However, we found that deficiency in *dnaQ* increased the mutation frequency (number
102 of mutants per cell plated in a single culture) of rifampicin resistance (Rif^R) by 3-fold ($P<0.05$) and
103 this phenotype can be complemented by expression of wild-type *dnaQ* from either *Msm* or *Mtb* strain
104 H37Rv, but not by the expression of exonuclease activity deficient variant (Exo⁻)
105 DnaQ[D28A/E30A/D112A] (**Fig. 1A**).

106 Because the fluctuation analysis assay relies on the selection of mutant (e.g., Rif^R) harboring
107 mutations in a specific locus (e.g., *rpoB*), the estimated mutation rate may not be representative of
108 the genome. In addition, because selection is likely to affect putatively neutral sites, this method
109 may have significant bias on detection of mutational events^{16,17}. To accurately determine the
110 mutation rate, we next deployed the MA experiment combined with whole-genome sequencing. For

111 each strain, 10~12 MA lines were initiated from a single colony (**Table 1**). Every 2 d, a single colony
112 from each line was re-streaked onto a fresh 7H10 plate. In this process, the strong bottlenecks
113 minimize the selective pressure, enabling mutations to accumulate in a neutral unbiased manner.
114 The application of whole-genome sequencing to MA lines further ensures the detection of complete
115 and nearly unbiased profile of mutational events^{5,16,17}. The MA experiment was carried out for 100
116 days, which accounted for > 8150 generations for each strain (**Table 1**). Totally 44 MA lineages
117 were successfully sequenced, with an average of 99.96% of the reference genome were covered
118 with >10x reads (**Supplemental dataset 1**). Through identify the base pair substitutions (BPSs) and
119 insertions/deletions (indels, defined as insertions or deletions of ≤ 30 nucleotides) (**Supplemental**
120 **dataset 1**), we found that the basal mutation rate for *Msm* wild type (WT) was 4.88×10^{-10} mutations
121 per base pair per generation (95% CI: [2.97-6.78] $\times 10^{-10}$), consistent with the estimates of
122 previously studies (95% CI: [4.52-5.27] $\times 10^{-10}$)^{11,18}. Among the mutant strains, the mutation rate of
123 the $\Delta dnaQ$ strain was 11.68×10^{-10} mutations per base pair per generation (95% CI: [7.05-16.31] \times
124 10^{-10}), a 2.4-fold increase over the WT (**Table 1**). Deletion of the *dnaQ* homolog encoded by *Ms4259*
125 either in the *dnaQ⁺* ($\Delta Ms4259$) or in the $\Delta dnaQ$ strain ($\Delta dnaQ\Delta Ms4259$) resulted in moderate
126 increase (~1.4-fold) of mutation rate (**Table 1**).

127 **Depletion of DnaQ leads to a mutation bias for AT and increased indels in homopolymeric
128 tract**

129 In WT, we identified totally 23 BPSs across the 12 lineages, showing a transition/transversion ratio
130 of 1.30 (13/10) (**Table S2**), which is very similar to the previous observation (1.48)¹⁸. However, this
131 ratio was elevated to 2.13 (34/16) in the $\Delta dnaQ$ mutant, yielding a 3.1-fold ($P < 0.001$) increase of
132 transition mutation rate over the WT (**Fig. 1B** and **Table S3**). Among the transitions, the G:C>A:T
133 mutation rate significantly increased 4.2-fold ($P < 0.01$) in the $\Delta dnaQ$ mutant compared to that of the
134 WT (**Fig. 1B** and **Table S3**). Given that the G:C>A:T mutation has a great influence on genomic GC
135 content during long-term evolution¹⁹, we analyzed the direction of mutation bias (**Fig. 1C** and **Table**
136 **S4**). In WT, the mutation rate of A/T>G/C (i.e. A to G or C, T to G or C) and G/C>A/T normalized to
137 the genomic GC or AT content are 3.40×10^{-10} and 2.69×10^{-10} , respectively, thus exhibiting a
138 mutation bias for GC (expected GC content is 55.8%, the actual genomic GC content of *Msm* is
139 65.6%), which is consistent to previous MA study (expected GC content was 58.2%)¹⁸. In contrast,
140 while the mutation rate of A/T>G/C remained unchanged in the $\Delta dnaQ$ mutant, the G/C>A/T
141 mutation rate (95% CI: [4.75-13.98] $\times 10^{-10}$) significantly increased 3.5-fold ($P < 0.01$), resulting in a
142 striking bias for AT mutation (expected GC content of 37.4%) (**Fig. 1C**). Deletion of the *dnaQ*
143 homolog (*Ms4259*) in the $\Delta dnaQ$ background ($\Delta dnaQ\Delta Ms4259$) resulted in similar mutation spectra
144 and mutational bias for AT as that of the $\Delta dnaQ$ mutant, however, these effects were not observed
145 in the $\Delta Ms4259$ mutant (**Fig. 1B-C**, **Table S3** and **Table S4**). Together, these results indicate that
146 mycobacterial *dnaQ* implicates in maintenance of genomic GC content. Of note, the mutation

147 spectrum of the mycobacterial $\Delta dnaQ$ mutant is quite distinct from that of the *E. coli* mutant deficient
148 in *dnaQ*, which showed a mutation bias for transversion and no effect on GC content²⁰.

149 Our MA analysis identified totally 44 indels 1-30 bp in length (**Table 1** and **Supplemental dataset**
150 **1**), and all strains exhibited a mutational bias for insertion events (**Table S2**). The indel rate of WT
151 (1.48×10^{-10}) is very similar to the previous estimate (1.27×10^{-10})¹⁸. While the $\Delta dnaQ$ mutant
152 showed a 1.9-fold increase of indel mutation rate (**Table S5**), the rate in the $\Delta Ms4259$ strain exhibited
153 a slightly reduction, suggesting a functional departure between DnaQ and Ms4259. Strikingly, the
154 indel events in the $\Delta dnaQ$, $\Delta Ms4259$ and $\Delta dnaQ\Delta Ms4259$ mutants occurred more frequently in the
155 lagging strands (62.5%, 71% and 73%, respectively) than that of the WT (40%) (**Supplemental**
156 **dataset 1**). In the WT and the $\Delta Ms4259$ strain, about 40% of the indels occurred in homopolymer
157 tract. However, these fractions were increased to 63% and 82% in the $\Delta dnaQ$ mutant and the
158 $\Delta dnaQ\Delta Ms4259$ mutant, respectively (**Table S5**). Accordingly, the mutation rate of indels occurred
159 in homopolymeric tract (almost G/C tract) was significantly increased 3-fold ($P<0.05$) in the $\Delta dnaQ$
160 mutant compared to the WT (**Fig. 1D** and **Table S5**). Moreover, indels events occurred in
161 homopolymeric tract less than 5 nucleotides in length were exclusively observed in the $\Delta dnaQ$
162 mutant and the $\Delta dnaQ\Delta Ms4259$ mutant (**Fig. 1D** and **Table S6**). Given that indel events in the
163 homopolymeric tract is mainly caused by strand slippage of replicative DNA polymerase²¹, these
164 results indicate a role of mycobacterial *dnaQ* in DNA replication. Of note, recent studies showed that
165 the indel events occurred in homopolymeric tract may have a strong impact on *Mtb*'s pathogenesis
166 and drug tolerance²²⁻²⁴.

167 Collectively, the MA results established that mycobacterial *dnaQ* contributes to the maintenance of
168 genetic information. Besides, our data indicated that the second potential DnaQ homolog encoded
169 by *Ms4259* exhibits distinctive mutational phenotypes from the annotated *Msm* DnaQ. Our results
170 also showed that the $\Delta Ms4259$ mutant exhibited a mutation bias for noncoding region (account for
171 31% of the BPSs) (**Table S2**), which is significantly different from that of the $\Delta dnaQ$ mutant (8%)
172 and from the expected value of 10% ($\chi^2=16.6$, $P<0.01$). Therefore, our data indicate that the second
173 potential DnaQ homolog encoded in mycobacteria is functionally distinct from the annotated DnaQ.

174 **Mycobacterial DnaQ specifically corrects DNA replication errors**

175 Spontaneous mutations can arise through replication errors or as a consequence of intrinsic DNA
176 damage¹⁷. To determine whether the anti-mutational role of mycobacterial *dnaQ* is attributable to
177 the correction of DNA replication errors, we performed fluctuation analysis and compared the
178 mutational rate of WT and the $\Delta dnaQ$ mutant expressing DanE1[D228N] variant which is deficient
179 in PHP domain-mediated proofreading¹¹. Expression of DanE1[D228N] did not affect bacterial
180 growth (**Fig. S2C**). While expression of wild-type *dnaE1* had no effect on the mutation rate in either
181 the *dnaQ⁺* prototype strain (95% CI: $[2.21-4.07] \times 10^{-9}$) or the $\Delta dnaQ$ mutant strain (95% CI: $[2.11-$
182 $4.01] \times 10^{-9}$), expression of DanE1[D228N] resulted in 9-fold increase of mutation rate in WT (95%
183 CI: $[2.21-3.41] \times 10^{-8}$) and 17-fold in the $\Delta dnaQ$ mutant (95% CI: $[4.18-5.95] \times 10^{-8}$) (**Fig. 2A**).

184 Therefore, the combination of *dnaQ* depletion and the deficiency in PHP proofreading activity results
185 in a synergistical effect on mutagenesis, demonstrating that mycobacterial DnaQ participates in
186 correction of replication errors.

187 To investigate whether DnaQ interacts with the replisome, we next performed *in vivo* immunoprecipitation using the Δ *dnaQ* mutant expressing DnaQ fusion protein containing a FLAG tag at either N-terminal (DnaQ_N-FLAG) or C-terminal (DnaQ_C-FLAG). Mass spectroscopy results demonstrated that immunoprecipitation of whole-cell lysates with FLAG antibodies coprecipitated DnaN and a protein with unknown function (*Ms4272*) from the strain expressing DnaQ_N-FLAG, but not from the lysate containing DnaQ_C-FLAG or untagged DnaQ (**Fig. 2B-C and Fig. S3A-C**). DnaN is the β subunit of DNA polymerase III holoenzyme, associates in pairs to form the β -clamp that encircles and slides along the DNA strands as replication proceeds. We found that mycobacterial DnaQ contains a highly conserved CBM Q[Y/L]ALF at its C-terminal proximity and the pulldown results demonstrated that this CBM is essential for the direct interaction between DnaQ and DnaN *in vitro*²⁵ (**Fig. 2D-E**). Therefore, the inability of DnaQ_C-FLAG to coprecipitate DnaN may likely be due to the inaccessibility of CBM to DnaN caused by the fused tag. Further, our *in vitro* 3'-5' exonuclease enzyme assay demonstrated that the presence of DnaN could increase the 3'-5' exonuclease activity of DnaQ (**Fig. 2F and Fig. S3D**), suggesting that DnaQ biochemically prefers to act at the replication fork. Unlike *E. coli*, whereby the DnaQ interacts with both the β -clamp and the α subunit of DNA polymerase III (**Fig. S1B**)²⁶, our results indicated that mycobacterial DnaQ did not form a stable complex with DnaE1, which are consistent with previous finding¹¹.

204 In bacteria, the replication sliding clamp also recruits DNA repair proteins to the replication forks²⁵. To
205 assess whether mycobacterial DnaQ plays a role in DNA damage repair, we measured the stress-
206 induced mutation frequency of rifampicin resistance (Rif^R) in strains exposed to hydrogen peroxide
207 (H₂O₂) or UV radiation, which are the most common source of endogenous and exogenous DNA
208 damage, respectively²⁷. Exposure of the WT to H₂O₂ and UV led to 4- and 90-fold increases of the
209 Rif^R frequency, respectively (**Fig. 1A and 2G**). However, these stress-induced mutations were
210 independent of *dnaQ*, as the Δ *dnaQ* mutant exhibited similar Rif^R frequency to WT (**Fig. 2G**). These
211 results collectively indicate that mycobacterial DnaQ does not function in DNA damage repair.

212 **Depletion of DnaQ results in replication fork perturbation upon topological stress**

213 The above results indicate that mycobacterial replisome may deploy two proofreaders (the PHP
214 domain of DnaE1 and DnaQ) to correct replication errors. To further explore the physiological role
215 of DnaQ, the additional proofreader, we performed transcriptional profiling and analyzed the DNA
216 damage response (DDR) signature during normal growth. Mycobacterial cell deploys sophisticated
217 regulatory systems that governs DDR against different types of DNA insults²⁸. According to the
218 previously published criteria (log₂ fold change of ≥ 1.5 , FDR<0.001)²⁸, 46 DDR genes showed
219 differential regulation (mostly upregulated vs the *dnaQ*⁺ prototype strain) in the Δ *dnaQ* mutant,

220 accounting for 40% of the differentially regulated genes (46/114) (**Fig. 3A, Supplementary dataset**
221 **2**). In contrast, only 3 DDR genes were upregulated in the Δ Ms4259 mutant strain. Strikingly, a
222 dominant proportion (33/46) of the differentially expressed DDR genes in the Δ dnaQ mutant belongs
223 to the PafBC regulon²⁸, resulting in an enrichment over 29-fold ($P<10^{-15}$, Fisher's exact test) (**Fig.**
224 **3B and Fig. S4A**). These transcriptional signatures were further validated by qRT-PCR (**Fig. S4B**).
225 Because the PafBC regulator responses specifically to quinolone antibiotics and replication fork
226 perturbation²⁸, as signified by the upregulation of the well-characterized recombinational fork-repair
227 genes including *recBC*, *adnAB* and *sbcD* (**Fig. 3C**)²⁹⁻³¹, these results demonstrate that DnaQ
228 deficiency leads to dysfunction of replication fork during normal growth. In contrast to *E. coli* *dnaQ*
229 mutant strain, which exhibited constitutive SOS phenotype and growth defect⁹, we did not observe
230 apparent SOS signature in the *Msm* Δ dnaQ mutant during normal growth (**Supplementary dataset**
231 **2**). Further, our qRT-PCR results indicated that deletion of *dnaQ* had no impact on the induction of
232 DNA repair genes under oxidative stress (**Fig. S4C**).

233 Given that no growth defect was observed in the *dnaQ* mutant (**Fig. S2B**), as well as the inability of
234 Exo⁻ DnaQ variant to restore the Rif^R frequency in the Δ dnaQ mutant (**Fig. 1A**), we conclude that
235 DnaQ depletion unlikely impairs the assembly of replisome during normal growth^{9,10}. Therefore, the
236 enriched upregulation of PafBC regulon genes in the Δ dnaQ mutant may likely reflect a replication
237 conflict under certain circumstance^{27,32}. To identify this condition, we examined the susceptibility of
238 the *dnaQ*⁺ prototype and the Δ dnaQ mutant to a panel of replication inhibitors and genotoxic agents.
239 We observed no difference in growth or survival between WT and the Δ dnaQ mutant in the presence
240 of DNA damaging agents 4-nitroquinoline-1-oxide (4NQO), UV (cause cyclobutene pyrimidine
241 dimers, cross-links and strand breaks) and reactive oxygen species (menadione and tert-butyl
242 hydroperoxide), the crosslinking and alkylating agents mitomycin C, or the topoisomerase IV
243 (function in separation of two catenated circular chromosomes to terminate replication) inhibitor
244 etoposide (**Fig. S5A-D**). However, the Δ dnaQ mutant exhibited attenuated growth compared with
245 the *dnaQ*⁺ prototype upon exposure to sub-minimal inhibitory concentration (MIC) of DNA gyrase A
246 inhibitor ofloxacin (Ofx, MIC 0.3 μ g/ml) (**Fig. 3D and Fig. S5E**). This growth defect can be fully
247 restored by expression of wild-type *dnaQ*, but not of the Exo⁻ DnaQ variant, indicating that the
248 maintenance of cell growth upon perturbations on gyrase activity relies on DnaQ's exonuclease
249 activity (**Fig. 3D**). Unlike the *E. coli* *dnaQ* mutant, our results showed that deletion of *dnaQ* in *Msm*
250 did not affect the ofloxacin MIC as well as the survival ability upon exposure to bactericidal
251 concentrations of ofloxacin (1.5 μ g/ml), suggesting that mycobacterial DnaQ does not implicate in
252 the fluoroquinolone-mediated killing (**Fig. S5F-G**)^{33,34}.

253 **Mycobacterial DnaQ sustains DNA replication fidelity upon topological stress**

254 At low concentration of fluoroquinolone, gyrase is reversibly trapped on DNA, thereby causing the
255 fork to stall^{35,36}. Therefore, fluoroquinolone-induced topological stress may affect bacterial growth
256 via perturbations to DNA replication, transcription or DNA damage such as SOS response²⁷.

257 Because no growth or survival defect was observed in the $\Delta dnaQ$ mutant upon exposure to UV and
258 a variety of genotoxic agents (**Fig. S5A-D**), we conclude that DNA damage is unlikely to be a
259 causative reason for the growth defect of the $\Delta dnaQ$ mutant upon exposed to sub-MIC Ofx. Our
260 results also demonstrated that this growth defect is not dependent on perturbations to transcription,
261 as no growth and survival difference was observed between the WT and the $\Delta dnaQ$ mutant exposed
262 to rifampicin (**Fig. S5E**).

263 Previous studies found that growth of bacterial cells upon exposure to sub-MIC fluoroquinolone is
264 largely dependent on the efficacy of DNA replication^{37,38}, which could be well reflected by bacterial
265 exponential growth rate³⁹. We therefore measured the growth rate of wild-type and DnaQ-depleted
266 strains exposed to sub-MIC of Ofx (**Fig. 3E**). Whereas both strains showed Ofx concentration-
267 dependent inhibition of growth, the $\Delta dnaQ$ mutant exhibited a rate of growth ~90% that of WT in the
268 presence of 0.33 \times or 0.5 \times MIC of Ofx (0.1 and 0.2 μ g/ml) ($P<0.05$). Expression of the wild-type *dnaQ*
269 in the mutant strain could completely restore the growth defect (**Fig. 3E**). Further, we found that,
270 when cultivated in the presence of sub-MIC Ofx, the $\Delta dnaQ$ mutant exhibited increased Rif^R
271 frequency over that of the WT ($P<0.05$) (**Fig. 3F**), indicating that *dnaQ* deficiency leads to increased
272 mutagenesis upon topological stress. Considering that no growth/survival defect was observed in
273 the $\Delta dnaQ$ mutant exposed to UV and chemical agents which could also lead to stalled replication
274 forks when the replisome encounters DNA lesions³², these results thus support a model whereby
275 mycobacterial DnaQ resolves fork conflict that is specifically induced by topological stress. This
276 speculation could be further supported by the observation that *dnaQ* is the only ciprofloxacin-
277 responsive gene that was upregulated in both *Msm* and *Mtb*²⁸.

278 ***dnaQ* is subject to positive selection in L4.3/LAM sublineage**

279 To assess whether the existence of an additional proofreader in mycobacteria provides an
280 alternative avenue for *Mtb* evolution in the real-world, we analyzed the *dnaQ* sequences of globally
281 collected 51,229 clinical *Mtb* isolates⁴⁰. Compared with the most recent common ancestor (MRCA)
282 DnaQ of *Mtb* complex (MTBC), we identified two lineage-defining mutations of DnaQ, with DnaQ
283 A164V affecting L7 and L2-L4 and DnaQ D76G affecting L4 (**Fig. 4A**). While *dnaE1* was under
284 strong purifying selection (dN/dS: 0.44), we found the selective pressure on *dnaQ* was close to
285 neutral (dN/dS: 0.97). This could be explained as either relaxed purifying selection or a mixture of
286 positive and negative selection on *dnaQ*. We further tested the selection on *dnaQ* in different
287 sublineages and found that *dnaQ* was under positive selection in some sublineages while under
288 negative selection in other sublineages (**Table S7**). The strongest positive selection was found in
289 L4.3 sublineage that was also previously known as LAM sublineage and considered to be a
290 generalist with worldwide distribution⁴¹. In total, we observed 31 mutational events of *dnaQ* in L4.3
291 with 26 of them being nonsynonymous (dN/dS: 1.96) (**Table S7**). Among these mutations, *dnaQ*
292 V88A arose at early stage of L4.3 diversification and affected 16.5% (1,203/7,284) of L4.3 strains,
293 G151R mutation also arose at mid-root position and formed a clade (**Fig. 4B** and **Fig. S1B**). The

294 positive selection on *dnaQ* suggested that the mutations might have functional effects on the
295 mutation rate of L4.3 strains. Therefore, we compared the number of SNPs accumulated in *dnaQ*-
296 WT and *dnaQ*-mutants. Overall, *dnaQ* mutants averagely accumulated 14 more SNPs than *dnaQ*-
297 WT strains ($P<0.0001$, Mann–Whitney U test) (Fig. 4C). We also found *dnaQ* V88A and G151R
298 clades had longer tip-to-root lengths as compared to their closest neighbors without *dnaQ* mutation,
299 further suggesting the naturally selected *dnaQ* mutants have functional effects on *Mtb* mutation rate
300 (Fig. 4B).

301 **Naturally selected *dnaQ*[V88A] enables hypermutability and is associated with extensive**
302 **drug resistance**

303 To experimentally investigate whether the naturally selected DnaQ variants would alter mutation rate,
304 we introduced *dnaQ* mutants in the *dnaQ*-null *Msm* or *Mtb* strain H37Rv via an integrative plasmid,
305 from which the *dnaQ* allele is expressed via a constitutive promoter. Expression of these DnaQ
306 variants in *Msm* did not affect bacterial growth (Fig. S2D). By fluctuation analyses, we found the
307 DnaQ[V88A] mutant prevalent in L4.3 caused 6-fold ($P<0.0001$) increase of the mutation rate
308 compared with strain expressing the ancestral-type DnaQ (Fig. 4D), while other natural variants in
309 the clinical isolates did not affect mutation rate. In agreement with the *Msm* results, expression of
310 DnaQ[V88A] in the Δ *dnaQ* mutant of *Mtb* strain H37Rv also increased the mutation rate by 6-fold
311 ($P<0.0001$) (Fig. 4E). These results indicated that the naturally selected *dnaQ*[V88A] is a mutator
312 gene and leads to an intermediate potent of hypermutability¹². Interestingly, expression of Exo- DnaQ
313 variant in the *Msm* Δ *dnaQ* strain only led to 2.4-fold increase of mutation rate (Fig. 1A), suggesting
314 V88A's effect might not just simply impair DnaQ exnuclease activity. Early structural and functional
315 studies showed that the residue M85 of the *E. coli* DnaQ (corresponding to V88 of *Mtb* DnaQ) is
316 located at α helix 3, a region that connects the exo I and exo II motifs and comprises the active site
317 along with α helix 7 and the edges of β sheets 1–3 (Fig. S1B)^{42,43}. However, the role of this region
318 in the non-canonical DnaQ remains unclear.

319 Early studies in *E. coli*, *Salmonella* and *Pseudomonas aeruginosa* pathogens showed that the
320 naturally selected mutators were frequently associated with inactivated MMR and multidrug
321 resistance (MDR)^{44,45}. In line with this, a mathematic modeling study in *Mtb* showed that strains with
322 ~8-fold increased mutation rate could give rise to a notably increased risk of MDR⁴⁶. These
323 observations predict that the DnaQ[A88]-harboring *Mtb* isolates would be more potent to become
324 resistant to multidrug. To test this, we compared the number of drug-resistant mutations identified in
325 each isolate between the DnaQ[A88]-harboring population (n=1174; 670 of them contain at least
326 one drug-resistant mutation) and the closest phylogenetic neighboring isolates containing DnaQ[V88]
327 (n=801; 556 of them contain at least one drug-resistant mutation) (Supplementary dataset 3)^{40,47}.
328 These isolates were distributed among 58 countries. Among the isolates containing at least one
329 drug-resistant mutation, those containing DnaQ[A88] accumulated more drug-resistant mutations
330 than the DnaQ[V88] isolates (mean, 6.6 vs 3.8; median, 6 vs 4) (Fig. 4F). Further analyses of

331 resistance to individual drug found that the drug-resistant mutations in DnaQ[A88]-harboring isolates
332 were associated with resistance to the second-line drugs, including levofloxacin, moxifloxacin,
333 ethionamide and the injectable drug kanamycin (**Fig. 4G**). Accordingly, the proportion of isolates
334 resistance to 5-11 drugs showed 2.2-fold increase in the DnaQ[A88]-harboring isolates over that of
335 the DnaQ[V88] (36.7% vs 16.9%). To assess whether national medical system has an influence on
336 these results, we further looked at *Mtb* isolates from Peru and UK, where each had >30 sequenced
337 isolates containing DnaQ[V88] or DnaQ[A88]. Again, at both countries, the proportion of *Mtb* isolates
338 resistant to 5-11 drugs increased at least one-fold in the DnaQ[A88] isolates than that of the
339 DnaQ[V88] isolates (**Fig. 4H**). Together, these data provided supportive evidence that DnaQ[A88]
340 may facilitate the *de novo* generation of drug-resistance mutations.

341

342 **Discussion**

343 During DNA replication, a high level of fidelity is attained by the proofreading activity. In *E. coli* and
344 other bacteria that use only one Pol III replicase (DnaE), proofreading is committed by the ϵ subunit
345 3'-5' exonuclease DnaQ⁴. In thermophiles and mycobacteria, proofreading is mediated by an
346 intrinsic 3'-5' exonuclease activity posed by the PHP domain of replicative polymerase DnaE1^{11,14,48}.
347 Based on phylogenetic and structural analyses, it has speculated that proofreading in most bacteria
348 may rely on the PHP exonuclease despite the presence of DnaQ homolog^{4,11,49}. However, the
349 biological function of this kind of alternative DnaQ exonuclease remains poorly understood. Here,
350 we showed that the mycobacterial DnaQ is an alternative proofreader and exhibits additional role in
351 maintenance of genomic GC content and sustaining DNA replication fidelity upon chromosome
352 topological stress. These results demonstrate that mycobacterial replisome may deploy two
353 proofreaders to maintain DNA replication fidelity (**Fig. 5A**).

354 Independent lines of evidence presented in this study indicate that mycobacterial 3'-5' exonuclease
355 DnaQ functions in maintaining replicative fidelity. The MA results showed that deletion of *dnaQ* led
356 to significantly increased mutation rate, which is perceived to be largely determined by the replication
357 fidelity of DNA polymerases^{5,16,18}. Previous study deploying fluctuation analysis found that deletion
358 of *dnaQ* in *Mtb* or in *Msm* did not significantly affect the mutation rate¹¹. This discrepancy may be
359 largely due to the difference on the methodology of detecting mutations¹⁶⁻¹⁸. The application of
360 whole-genome sequencing to MA experiment enables complete and nearly unbiased determination
361 of mutation events occurred in a neutral manner¹⁶. Further, previous study showed that expression
362 of replicative polymerase DnaE1 with inactivated PHP exonuclease activity leads to accumulation
363 of replicative errors in mycobacteria¹¹. Therefore, the synergistical effect of DnaQ depletion and
364 inactivation of PHP-mediated proofreading on mutagenesis signifies that DnaQ could partially rectify
365 the replicative errors produced upon PHP inactivation. Importantly, the results of *in vivo*
366 immunoprecipitation and *in vitro* pulldown assay collectively provide biochemical evidence that

367 mycobacterial DnaQ binds to the replication sliding clamp via its C-terminal CBM motif, thus
368 establishing a functional relation of DnaQ with replisome. Finally, our enzyme assays showed that
369 the interaction with DnaN substantially stimulates DnaQ 3'-5' exonuclease activity. Based on these
370 data, taken together with the irrelevance of DnaQ on stress-induced mutagenesis, we conclude that
371 mycobacterial DnaQ represents an alternative proofreading exonuclease that works together with
372 the PHP exonuclease to maintain replicative fidelity.

373 Our MA data showed that, unlike the *E. coli* DnaQ, mycobacterial DnaQ exhibits additional role in
374 maintenance of genomic GC content. How does mycobacterial DnaQ maintain GC content?
375 Previous studies in *Salmonella* Typhimurium and *Msm* indicated that the AT-biased mutation is
376 associated with mismatches caused by oxidized and deaminated DNA bases⁵⁰⁻⁵². In both organisms,
377 mutants deficient in base excision repair systems (Ung, MutY or MutM) that target oxidized and
378 deaminated DNA bases showed strong increase of AT-biased spontaneous mutations. However, our
379 data indicated that *dnaQ* deletion-induced AT-biased mutations may not arise from oxidative DNA
380 damage, as exposure of the mutant to H₂O₂ resulted in similar mutation frequency as that of wild-
381 type *Msm*. We propose that mycobacterial DnaQ may preferably rectify the A/T•G/C mismatches
382 (primer•template, *i.e.* A mismatches with G or C, and T mismatches with G or C), according to the
383 following two observations: (1) mycobacterial DnaQ specifically corrects replicative errors, and (2)
384 deletion of *dnaQ* did not affect the A/T>G/C mutation rate. According to the structural data on
385 thermophilic *Bacillus* high-fidelity DNA polymerase I fragment (BF) complexed with mismatched
386 DNA, bacterial replicative DNA polymerases are more prone to extend G•T, C•T, and G•G
387 mismatches (leading to T>C, T>G and G>C mutation), but unable to extend A/T•G/C mismatches
388 (leading to G/C>T or G/C>A mutation) due to distortions both in the polymerase catalytic site and
389 DNA strand (template and/or primer) geometry⁵³. Because of the strong impact of A/T•G/C
390 mismatches on geometry of template and/or primer strand, it is possible that the active sites of
391 intramolecular exonuclease cannot efficiently adapt to this geometry change on DNA⁵⁴ (**Fig. 5B**).
392 This speculation could be supported by a recent cryo-EM study of the *E. coli* replisome catalytic
393 core, showing that the T•C mismatch increases the fraying of the 3' terminus of the primer and thus
394 enables a ~55 Å translocation from the polymerase to the DnaQ exonuclease active site⁵⁵. Further
395 biochemical and structural studies are needed to fully elucidate the mechanisms underlying DnaQ's
396 substrate preference.

397 Our study also revealed a role of mycobacterial DnaQ's 3'-5' exonuclease activity in sustaining of
398 DNA replication fidelity upon chromosomal topological stress. In contrast to the *E. coli* mutant
399 deficient in *dnaQ*, which exhibited increased sensitivity to a variety of chemicals that interact with
400 DNA or inhibit DNA synthesis³³, our screen against a panel of genotoxic agents showed that the
401 Δ *dnaQ* mutant *Msm* is only sensitive to sub-MIC of gyrase inhibitor Ofx. These results indicate that
402 the *dnaQ* deletion-induced growth attenuation in the presence of sub-MIC of Ofx may stem from
403 replication conflicts specifically induced upon topological stress (**Fig. 5C**), rather than because of

404 impaired assembly and functioning of replisome as observed in *E. coli* strains defective in DnaQ^{9,10,26}.
405 The mild upregulation of PafBC regulon genes in the Δ dnaQ mutant under normal growth condition
406 suggest that topological stress may occasionally occur in *Msm* despite the presence of a functional
407 gyrase. In this direction, it's noteworthy that increasing evidence shows that gyrase alone is not
408 sufficient to resolve topological stress during bacterial replication^{56,57}. For instance, it was found that
409 GapR, a chromosome structuring protein of *Caulobacter crescentus*, participated in resolution of
410 topological stress by regulation gyrase activity⁵⁷.

411 The positive selection of *dnaQ* variations prevalent in *Mtb* L4.3/LAM sublineage provides evidence
412 that DnaQ may play a crucial role in *Mtb*'s adaptation. Of the two clade-forming DnaQ mutations
413 (V88A and G151R), our fluctuation analyses results demonstrated that the DnaQ[V88A] variant
414 lead to an intermediate potent of hypermutability in both *Mtb* and *Msm*¹². Analyses of the clinical
415 isolates sequence data showed that the DnaQ[A88]-harboring *Mtb* accumulated more drug-
416 resistant mutations and were more frequently associated with resistance to the second-line drugs.
417 These results are consistent with the previous findings in the naturally evolved mutators of Gram-
418 negative pathogens and the mathematic modeling study in *Mtb*, showing that strains with such an
419 increased basal mutation rate could give rise to a notably increased risk of acquiring resistance
420 to multidrug^{12,44-46}. According to these results, we propose that patients infected with *Mtb*
421 DnaQ[V88A] strain may have increased risk of treatment failures due to increased potent of this
422 strain to acquire drug-resistant mutations. We found that the expression of DnaQ[G151R] did not
423 results in increased mutation rate, as measured by fluctuation analysis, suggesting that the
424 functional effect of this mutation may differ from that of V88A.

425 How does DnaQ[V88A] lead to increased mutagenesis? Our results showed that the expression
426 of DnaQ[V88A] led to a notable increase of mutation rate over that of the *dnaQ*-deletion mutant
427 or the strain expressing the DnaQ variant deficient in the 3'-5' exonuclease activity. These results
428 indicate that the mutational effect of DnaQ[V88A] is unlikely stemmed from depletion of DnaQ-
429 mediated proofreading. Instead, this mutator phenotype may likely derive from perturbations on
430 other components that ensure replicative fidelity. Considering the replisome location of DnaQ, as
431 well as the lack of canonical MMR system in *Mycobacterium*³, a possible explanation is that the
432 V88A mutation of DnaQ affects DnaE1-mediated polymerization or/and proofreading (**Fig. 5D**).
433 This speculation could be supported by the published observations that the interaction between
434 *E.coli* DnaQ (ϵ subunit) and DnaE (α subunit) could influence replicative fidelity: (1) suppressor
435 mutations in *dnaE* could alleviate the growth defect and reduce the mutator phenotype of *dnaQ*
436 mutant^{58,59}, and (2) DnaQ binding enhances the stability of the clamp- α complex and the
437 polymerase processivity^{10,26}. Although our *in vivo* immunoprecipitation result did not observe an
438 interaction between mycobacterial DnaQ and DnaE1, previous *in vitro* study using the analytical
439 size exclusion chromatography showed an unstable binding between these two proteins¹¹,
440 providing evidence that mycobacterial DnaQ may interact with DnaE1 in certain circumstances.

441 Alternatively, DnaQ[V88A]-mediated mutagenesis may rely on the action of error-prone
442 polymerase such as DnaE2 (belong to the SOS regulon)^{15,60} (**Fig. 5D**). This model could be
443 supported by the findings that deletion of *E. coli dnaQ* resulted in constitutive SOS response and
444 this phenotype could be uncoupled from proofreading function⁴². Further experiments are
445 necessary to reveal the nature of DnaQ[V88A]-mediated mutagenesis, which may promote our
446 understanding of the dynamic regulation of mycobacterial proofreading activity.

447

448

449 **ACKNOWLEDGMENTS**

450 The work was supported by the National Natural Science Foundation (grant 81991532 and
451 31970032 to L.-D.L., 31830002 to G.-P. Z., 31800123 to Y.-Y.X.); the Shanghai Committee of
452 Science and Technology (grant ZD2021CY001 to L.-D.L.); the National Institutes of Health (grant
453 P01 AI132130 to S.M.F.).

454

455 **AUTHOR CONTRIBUTIONS**

456 Conceptualization, L.-D.L.; Methodology, L.-D.L., S.M.F., M.-Z.D. and Q.L.; Experiments, M.-Z.D.,
457 S.-J.C., F.H. Y.-Y.X. and X.C.; Clinical data analyses, Q.L. and M.Y.G.; Data analyses, M.-Z.D., Q.L.,
458 W.S. and L.-D.L.; Writing and editing, L.-D.L., Q.L., M.-Z.D. and G.-P.Z.; S.M.F. supervised the
459 clinical data analyses; L.-D.L. supervised the whole work.

460

461 **DECLARATION OF INTERESTS**

462 The authors declare no competing interests.

463

464 **Materials and Methods**

465

466 **Strains and mutants**

467 *M. smegmatis* mc²155 (ATCC 706) and *M. tuberculosis* H37Rv (ATCC 27294) were used in this
468 study⁶¹. Strains and primers used in this study were listed in **Table S8** and **Table S9**, respectively.
469 The knockout mutant strains were generated via allelic exchange using a specialized phage
470 transduction method⁶². To construct double deletion mutant, the hygromycin B-resistant gene in the
471 plasmid pYUB854 was replaced with the kanamycin-resistant gene *aph*, the resulting plasmid was
472 used to generate the allelic exchange construct. For expression of *dnaQ* and its variants, the *dnaQ*
473 alleles were amplified by PCR and cloned into an integrative single-copy plasmid pMV361, gene
474 expression was controlled by a constitutive *Msm* promoter (*groL1*). For expression of *DnaE1* and
475 *DnaE1[D228N]*, DNA sequences encoding N-terminal MYC-tagged *dnaE1* and *dnaE1[D228N]* were
476 PCR amplified and cloned into an episomal multicopy plasmid pMV261, expression was controlled
477 by a Tet-on expression system⁶³. All plasmids used in this study were verified by DNA sequencing.
478

479 **Culture conditions**

480 Mycobacterial strains were grown in Difco Middlebrook 7H9 broth (BD #271310) or on 7H10 (BD
481 #262710) agar with the supplementation of 0.5% glycerol, 0.05% Tween80 and 10% OADC (*Mtb*).
482 If applicable, hygromycin B (Hyg) or kanamycin (Kan) were added to a final concentration of 50
483 µg/mL or 20 µg/mL, respectively. Experimental cultures were started by inoculating overnight culture
484 into fresh media (without antibiotic) to achieve an OD₆₀₀ of 0.01~0.02, then incubating at 37 °C with
485 shaking at 100 rpm.
486

487 **Mutation accumulation assay**

488 MA assay was performed as previously described^{11,18}. *M. smegmatis* MA independent lines were
489 evolved in parallel starting from the parental strain wild-type mc²155 and its *dnaQ*-deficient mutants
490 (Δ *Ms4259*, Δ *dnaQ*, Δ *dnaQ* Δ *Ms4259*). For each genotype, 10~12 MA lines were initiated from a single
491 colony. Each line was streaked for single colonies on a 7H10 plate (without antibiotic) and incubated
492 for 2 days. This procedure was then followed repeatedly for the desired number of passages. The
493 bottlenecking procedure used for this experiment ensures that mutations accumulate in an
494 effectively neutral fashion. The number of generations (n) was then calculated by $n = \log_2 N$, with N
495 being the number of cells per colony. To estimate the number of cells in a generation colony, at least
496 10 colonies were excised from the agar plates, resuspended in PBST (PBS with 0.05% Tween 80)
497 to generate a single-cell suspension, and dilutions were plated on 7H10 plates. For wild-type mc²155,
498 Δ *Ms4259* and Δ *dnaQ* strains, the average number of cells in a colony was 7.66×10^4 cells, which
499 corresponds to 16.3 generations, while the Δ *dnaQ* Δ *Ms4259* strain was 3.94×10^5 cells and
500 corresponds to 18.6 generations.
501

502 **Whole genome sequencing analysis**

503 Genomic DNA was isolated from 10 mL *Msm* cultures using standard CTAB extraction method. DNA
504 concentration and purity were measured using a Qubit 3.0 fluorometer (Life Technologies) and a
505 NanoDrop-2000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). Whole-
506 genome sequencing libraries were constructed with the NEXTflex™ DNA Sequencing Kit compatible
507 with the Biomek® FXp (Bio Scientific) following the manufacturer's instructions. Sequencing was
508 performed on the Illumina X-10 instrument to obtain 300-bp paired-end reads. The obtained Illumina
509 reads were filtered with the Trimmomatic (version0.32) to remove low-quality bases and adapter.
510 After that, the filtered reads were aligned to the reference genome (NC_008596) with the short-read
511 alignment tool Bowtie2. Potential duplicates were removed with Picard tools. Mutation accumulation
512 lines were covered to an average depth of 194× (139-360×) and 99.9% genome coverage at a depth
513 greater than 10×. The variant calling was performed with SAMtools and Genome Analysis Toolkit⁶⁴.
514 A single-nucleotide polymorphism (SNP) and indels (≤ 30 bp) were called and filtered if (i) we have
515 at least 10 reads covering the site, (ii) it was found at a frequency of >0.8 . SNP that was observed
516 in all lines of a strain was excluded¹⁶.

517

518 **Estimate of mutation rate from MA assay**

519 The mutation rate was estimated as previously described^{11,16,52}. The estimation for the mutation rate
520 for a MA line was generated with the equation: $\mu = m/(N^*g)$. m is defined by the number of variants
521 (SNPs and indels) observed, N is determined based on $>99.9\%$ coverage of a 6,988,209 bp *Msm*
522 mc²155 genome, and g is an estimate of the number of generations that occurred during passaging.

523

524 **Fluctuation analysis**

525 Fluctuation analysis was performed as previously described⁴⁶. For each strain, starter cultures
526 inoculated from freezer stocks were grown to an OD₆₀₀ of ~ 0.8 , and then diluted by 7H9 to an OD₆₀₀
527 of 0.0001 ($\sim 10,000$ cells per ml). The diluted cultures were immediately split into ~ 30 cultures of 5
528 mL each in 30-mL square PETG culture bottles (Sangon Biotech) and grown at 37 °C with shaking
529 at 100 rpm to OD₆₀₀ of ~ 0.8 . Cell counts were determined by plating dilutions. The cell pellet from
530 4.5 mL culture was plated on 7H10 agar containing 100 μ g/mL rifampicin. The rifampicin-resistant
531 colonies were counted after culturing at 37 °C for 4 d. The mutation rate was calculated by the
532 FALCOR web tool found at <https://lianglab.brocku.ca/FALCOR/> using the Ma–Sandri–Sarkar
533 maximum likelihood method^{17,65,66}.

534

535 **Mutagenesis assay**

536 Mutagenesis assays were performed to measure the frequency of rifampicin resistance in a
537 population. The Rif^R mutation frequency was calculated by dividing the number of rifampicin-
538 resistant colonies on a rifampicin plate by the counts of the total viable cells plated. For H₂O₂-induced
539 mutagenesis, cultures at OD₆₀₀ of 0.8 were treated with 5 mM H₂O₂ for 2 h. For UV-induced
540 mutagenesis, 5 mL cultures (OD ~ 0.8) in 9-centimeter plate were exposed to 25 mJ/cm² UV radiation
541 with a Stratagene UV Stratalinker 1800. Plates were wrapped in foil to prevent potential effects of

542 photolyase and incubated at 37 °C for 3 h. For Ofx-induced mutagenesis, cells were inoculated into
543 5 mL 7H9 broth containing 0.1 µg/ml or 0.2 µg/ml Ofx in 30-mL square PETG culture bottles, grown
544 at 37 °C for 10 h. After treatment, cells were harvested by centrifugation, resuspended in 200 µL of
545 7H9 broth and plated on 7H10 agar plates containing 100 µg/mL rifampicin. Cell counts were
546 determined by plating dilutions.

547

548 **RNA isolation and sequencing**

549 *Msm* strains were grown in 10 mL 7H9 broth (in 150-mL flask) to an OD of 0.6-0.8. Cells were
550 harvested by centrifugation (3220×g, 5 min, 25 °C). Then, cell pellet was resuspended in 1 mL TRIzol
551 reagent (Ambion), mixed with 500 µL of 0.1mm zirconia-silicate beads. Cells were mechanically
552 disrupted by beads beating (Bertin, Minilys) for five cycles (35 s at maximal speed) with cooling on
553 ice for 1 min between pulses. The TRIZol-isolated RNA was treated with 10 U RNase-free DNaseI
554 (NEB) for 30 min at 37°C, further purified using the GeneJET RNA purification kit (Thermofisher).
555 The RNA quality was assessed using Agilent 2100 bioanalyzer. To remove rRNA, Ribo-Zero Plus
556 rRNA Depletion Kit (Illumina) was applied according to manufacturers' instructions. KAPA Stranded
557 mRNA-Seq Kit Illumina® platform was used to do the library-preparation. Libraries were sequenced
558 on Illumina HiSeq X-ten sequencing System with a read length of 150 base pairs (bps). Raw RNA-
559 seq reads were preprocessed through trimmomatic (version 0.39)⁶⁷. The preprocessed reads were
560 aligned against *Msm* genes using bowtie2 (version 2.3.5.1)⁶⁸. Gene-level read counts were
561 summarized with samtools (version 1.9). Gene expression difference between two samples were
562 obtained by MARS (MA-plot-based method with Random Sampling model), a package from
563 DEGseq⁶⁹. Genes with at least 1.5-fold change between two samples and FDR (false discovery rate)
564 less than 0.001 were defined as differentially expressed genes.

565

566 **Quantitative real time PCR**

567 cDNA was synthesized using the SuperScript™ IV First-Strand Synthesis System (Invitrogen) with
568 random hexamer primer. RT-qPCR was carried out using TB Green® Premix Ex Taq™ GC (TaKaRa,
569 RR071Q). Gene expression data were normalized to *sigA* and expressed as fold change using the
570 $2^{-\Delta\Delta Ct}$ method compared to wild-type strain or untreated control.

571

572 **Sensitivity assay**

573 For menadione sensitivity assay, cultures at exponential growth phase were diluted to an OD₆₀₀ of
574 0.001 in 3.5 mL prewarmed top agar (0.6% agarose), plated on 7H10 agar. Then, a filter paper was
575 placed on the top agar and spotted with 10 µL of 5 mM menadione. After incubation at 37 °C for 2~3
576 d, the diameter of the growth inhibition zone was measured. For agar-based sensitivity assays,
577 strains were grown to exponential phase and diluted to an OD₆₀₀ of 0.1. Serial dilutions were
578 performed from 10⁰ to 10⁻⁵ in 7H9 broth, and 5 µL each dilution was spotted on 7H10 agar containing
579 4-nitroquinoline-1-oxide (4NQO, 1.25, 2.5, 5 µM), mitomycin C (8, 16, 32 nM), etoposide (25, 50,
580 100 µM), ofloxacin (0.1, 0.2, 0.4 µg/mL), or rifampicin (5, 10, 20 µg/mL). Plates were imaged after

581 3~4 d incubation at 37 °C. To determine MIC, strain was grown in 7H9 broth (without the supplement
582 of antibiotic) to exponential phase, then the culture was diluted to an OD₆₀₀ of 0.001 in 200 µL 7H9
583 broth containing the appropriate concentration of antibiotic. All concentrations were tested in
584 triplicate. After cultivation at 37 °C for 3 d, cell growth was measured by OD₆₀₀. The percentage of
585 growth was calculated for each strain in each growth condition by normalizing the OD₆₀₀ to that of
586 the no-drug control.

587

588 **Killing assay**

589 Exponential-phase cultures were diluted to an OD₆₀₀ of 0.1 and treated with 1.5 µg/mL ofloxacin at
590 37 °C. For treatment with tert-Butyl hydroperoxide (tBHP), cultures at OD₆₀₀ of 0.6~0.8 were exposed
591 to 1 mM tBHP and incubated at 37 °C. Cell counts were determined by plating dilutions. For UV
592 exposure, serial tenfold dilutions were performed in 7H9 broth, and 5 µL of each dilution was spotted
593 on 7H10 agar. Agar plates were exposed to indicated doses of UV radiation with a Stratagene UV
594 Stratalinker 1800 with 254-nm UV bulbs. Plates were wrapped in foil (to prevent potential effects of
595 photolyase) and incubated at 37 °C.

596

597 **Measure of grate rate**

598 Experimental cultures were started by inoculating overnight culture into 20 mL fresh 7H9 broth (in a
599 150-mL flask) containing Ofx (0.07-0.3 µg/mL) to achieve an OD of ~0.02, then grown at 37 °C with
600 shaking at 100 rpm. The OD₆₀₀ value was measured every 1.5 h to obtain growth curves. The
601 experiments were independently repeated for two times. According to previous study⁷⁰, growth rate
602 was defined as $\mu=2.303(\lg OD_2 - \lg OD_1)/(t_2 - t_1)$ and was determined at an early time (0.1<OD<0.4)
603 when the OD value was linearly correlated with cell density. For each growth curve, we used several
604 time intervals to calculate the growth rate.

605

606 **Immunoprecipitation**

607 FLAG-tagged *dnaQ* under the control of native promoter was integrated at the *attB* site of the $\Delta dnaQ$
608 mutant strain. Cells were cultivated in 50 mL 7H9 broth (without antibiotic) in a 250-mL flask to an
609 OD of ~0.8, harvested by centrifugation at 3220× g, 5 min at 4 °C. Cell pellets were washed by 10
610 mL ice-cold PBS and subsequently resuspended in 0.5 mL cell lysis buffer (PBS, pH=8.0, 150 mM
611 NaCl, 0.25% NP-40, ice-cold) containing 250 µL of 0.1mm zirconia-silicate beads, lysed by bead
612 beating (Bertin, Minilys) for five cycles (35 s at maximal speed) with cooling on ice for 1 min between
613 pulses. The cell lysates were centrifuged at 18,000× g for 10 min at 4 °C, the supernatant was
614 collected for immunoprecipitation. Protein concentration was determined by the Bradford method
615 (Sigma-Aldrich, B6916). 50 µL magnetic beads (Invitrogen, 10007D) were washed and resuspended
616 in 200 µL Ab Bind and Wash Buffer (Invitrogen, 10007D) containing 8 µg Monoclonal ANTI-FLAG®
617 M2 antibody (Sigma Aldrich, F1804). After incubation at room temperate for 20 min, the beads were
618 washed by 200 µL Ab Bind and Wash Buffer, then mixed with 350 µL cell lysate supernatant (2-3 mg
619 protein) and 350 µL cell lysis buffer, incubated at 4 °C for 3 h with rolling. Then, the beads were

620 washed 5 times each with 200 μ L cell lysis buffer. Bead-bound proteins were eluted with elution
621 buffer (100 mM glycine-HCl, pH 3.0). The elutes were analyzed by SDS-PAGE using a Fast Silver
622 Stain Kit (Beyotime, P0017S), or store at -80 °C for LC-MS/MS analysis.

623

624 **Mass spectrometry**

625 The eluted sample was digested by trypsin at 37 °C for 16-18 h. The peptide mixture was loaded
626 onto a reverse phase trap column (Thermo Scientific Acclaim PepMap100, 100 μ m*2cm, nanoViper
627 C18) connected to the C18-reversed phase analytical column (Thermo Scientific Easy Column, 10
628 cm long, 75 μ m inner diameter, 3 μ m resin) in buffer A (0.1% Formic acid) and separated with a linear
629 gradient of buffer B (84% acetonitrile and 0.1% formic acid) at a flow rate of 300 nL/min controlled
630 by IntelliFlow technology. LC-MS/MS analysis was performed on a Q Exactive mass spectrometer
631 (Thermo Scientific) that was coupled to Easy nLC (Thermo Scientific) for 30/60/120/240 min
632 (determined by project proposal). The mass spectrometer was operated in positive ion mode. MS
633 data was acquired using a data-dependent top20 method dynamically choosing the most abundant
634 precursor ions from the survey scan (300-1800 m/z) for higher energy collision dissociation (HCD)
635 fragmentation. Automatic gain control (AGC) target was set to 1E6, maximum inject time to 50 ms,
636 and number of scan ranges to 1. Dynamic exclusion duration was 30.0 s. Survey scans were
637 acquired at a resolution of 70,000 at m/z 100 and resolution for HCD spectra was set to 17,500 at
638 m/z 100, AGC target was set to 1E5, isolation width was 1.5 m/z, microscans to 1, and maximum
639 inject time to 50 ms. Normalized collision energy was 27 eV and the underfill ratio, which specifies
640 the minimum percentage of the target value likely to be reached at maximum fill time, was defined
641 as 0.1%. The instrument was run with peptide recognition mode enabled. MS/MS spectra were
642 searched using MASCOT engine (Matrix Science, London, UK; version 2.2) against a nonredundant
643 International Protein Index arabidopsis sequence database v3.85 (released in September 2011;
644 39679 sequences) from the European Bioinformatics Institute (<http://www.ebi.ac.uk/>). For protein
645 identification, the following options were used. Peptide mass tolerance= 20 ppm, MS/MS tolerance=
646 0.1 Da, Enzyme=Trypsin, Missed cleavage= 2, Fixed modification: Carbamidomethyl (C), Variable
647 modification: Oxidation(M)

648

649 **Western Blotting**

650 Cell lysates was prepared as described in Immunoprecipitation. Approximately 50 μ g of total cell
651 proteins were resolved by 4%-20% SurePAGE, Bis-Tris (GenScript, M00657) at 120V for 1h and
652 detected by immunoblotting. Proteins were transferred to PVDF membrane (Millipore, IPVH00010)
653 at 20V, 4 °C for 1 h using a Mini Gel Tank (Life Technologies, A25977), blocked with blocking buffer
654 (20 mM Tris-HCl pH 7.6, 150 mM sodium chloride, 0.01% (w/v) Tween-20, 3% BSA) overnight at
655 4 °C, washed for 5 min at room temperature with TBST (20 mM Tris-HCl pH 7.6, 150 mM sodium
656 chloride, 0.01% (w/v) Tween-20) two times. For detecting FLAG-tagged DnaQ, the membrane was
657 incubated for 2 h at room temperature with a monoclonal anti-FLAG antibody (Sigma Aldrich, F1804)
658 diluted 1:1,000 in blocking buffer. Mycobacterial Hsp65 was detected using a monoclonal antibody

659 (Abnova, MAB4853) diluted 1:5,000. Membrane was washed for 5 min at room temperature with
660 TBST five times, incubated for 1 h at room temperature with an anti-mouse IgG secondary antibody
661 conjugated with peroxidase (Sigma Aldrich, A9044) diluted 1:10,000 in blocking buffer. Membrane
662 was washed for 5 min at room temperature with TBST two times, blot signals were visualized using
663 the SuperSignal™ West Pico PLUS (Thermo Scientific, 34577) and a chemiluminescence imaging
664 system (Tanon 5200).

665

666 **Protein expression and purification**

667 Wild-type *dnaQ*, *dnaQ_Cdel* and *dnaN* were cloned into the pET32a plasmid and transformed into
668 the *E. coli* BL21(DE3) strain. *E. coli* cells were cultivated in LB to an OD₆₀₀ of 0.6, expression was
669 induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 16 °C for 12 h. Cells were
670 harvested by centrifugation at 3220× g, 20 min at 4 °C, resuspended in buffer A (20 mM Tris-HCl,
671 pH 8.0, 0.5 M NaCl, 10% glycerol, 10 mM imidazole and 2 mM DTT) with protease inhibitor and
672 lysed by ultrasonication. Cell lysates were centrifuged at 18,000× g for 20 min at 4 °C to remove cell
673 debris and insoluble fraction. The resulting supernatant was applied to a 10-mL column with 1 mL
674 of Ni-Sepharose (GE Healthcare Life Sciences, 17531801) equilibrated with binding buffer (20 mM
675 Tris-HCl, pH 8.0, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 5 mM DTT). The target proteins
676 were eluted by 50 mM imidazole. The purified protein was concentrated to 5 mg/ml by ultrafiltration
677 (Millipore, UFC901096) and maintained in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM DTT, and
678 20% glycerol, divided into small aliquots, and stored at -80 °C. The protein concentration was
679 determined by the Bradford method.

680

681 **Pulldown assay**

682 To remove the N-terminal Trx_His_FLAG tag, the purified DnaN protein was digested by
683 recombinant enterokinase (1.2 U per 50 µg DnaN) at 4 °C for 20 min, then incubated with Ni-
684 Sepharose for 2 h at 4 °C. The elution containing native DnaN protein was concentrated by
685 ultrafiltration (Millipore, UFC901096) and maintained in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5
686 mM DTT. To perform pulldown assay, 30 µL Ni-Sepharose was pre-bound with ~200 µg His-tagged
687 DnaQ or DnaQ_Cdel for 5 min at 4 °C. After washing 2 times with 300 µL washing buffer (20 mM
688 Tris-HCl, pH 8.0, 100 mM NaCl, 10% glycerol and 25 mM imidazole), the pre-bound Ni-Sepharose
689 was mixed with ~200 µg native DnaN proteins and incubated at 4 °C for 5 min. The Ni-Sepharose
690 was washed 2 times and eluted with SDS-PAGE sample buffer. Elutions were analyzed by SDS-
691 PAGE using Coomassie blue staining (Beyotime, P0017).

692

693 **Exonuclease assay**

694 The N-terminal fusion tag of the purified DnaQ, DnaQ_Cdel and DnaN proteins were removed by
695 recombinant enterokinase as described in the pulldown assay. Protein concentration was
696 determined by Bradford method. Exonuclease assays were performed in 20 mM Tris-HCl, pH 8.0,
697 100 mM NaCl, 10% glycerol, 2 mM MgCl₂, 2 mM DTT and 50 µM BSA. Reactions were performed

698 at 25 °C with 5 nM purified protein and 38 nM DNA substrate 5'-FAM-GTTCACGAGACCTACTGAC
699 ACTGA-3', and stopped by adding 100 mM EDTA, pH 7.4. The reaction products were analyzed by
700 a denaturing 20% acrylamide gel and imaged with a Typhoon Imager (GE Healthcare).

701

702 **WGS data analysis**

703 Whole-genome sequencing data for 51,229 *Mtb* isolates from 203 SRA projects included in this
704 study were described previously⁴⁰. The tool *prefetch* (<https://www.ncbi.nlm.nih.gov/books/NBK242621/>) was used for downloading the *sra* files of the *Mtb* isolates. The downloaded *sra* files
705 were converted to paired-end or single-end *fastq* files using the toolkit of *fastq-dump*
706 (<https://www.ncbi.nlm.nih.gov/books/NBK158900/>). Samples with an average sequencing depth
707 over 20× and a mapping rate of over 90% were used for downstream analyses. Sequencing reads
708 were trimmed with *Sickle*⁷¹. Trimmed reads with length > 30 and Phred scores > 20 were retained
709 for subsequent analyses. The inferred ancestral genome of the most recent common ancestor of
710 the *MTBC* was used as the reference template for reads mapping⁷². Sequencing reads were
711 mapped to the reference genome using *Bowtie 2* (v2.2.9)⁶⁸. *SAMtools* (version 1.3.1) was used for
712 SNP calling with the minimal mapping quality set to be 30⁷³. We excluded SNPs located in repetitive
713 regions of the genome (e.g., PPE/PE-PGRS family genes, pro-phage genes, insertion, or mobile
714 genetic elements) that are difficult to characterize with short-read sequencing technologies⁷⁴. Fixed
715 SNPs with a frequency of ≥95% and at least 10 supporting reads were identified using *VarScan*
716 (v2.3.9) with the strand bias filter on. Small insertions or deletions (INDELs) identified by *VarScan*
717 (v2.3.9) were also excluded. *Mtb* isolates were typed into lineages based on the previously defined
718 lineage-specific barcode SNPs^{75,76}. We excluded isolates showing heterozygous typing results or
719 those that were missing lineage-defining SNPs in the lineage-associated analysis.

720 To test whether *dnaQ* was under positive selection in *Mtb* population, we used a previously
721 described method (pNpS) to generate mutations *in silico* through a random substitution process⁷⁷.
722 Briefly, a codon substitution matrix was generated using a base substitution model which considers
723 the genome's GC content (65.6% for *Mtb*) and the proportion of transitions that occurred at the
724 wobble position of codons in synonymous fixed mutations (Ti, 0.729). For each codon, a simulation
725 of 50,000 individual introductions of a single mutation was performed and the outcomes were scored
726 as either synonymous or nonsynonymous. The average number of nonsynonymous outcomes of
727 the simulations is an estimate of the probability that a mutation in the given codon would be
728 nonsynonymous.

729

730 **Statistical analysis**

731 Significance tests were performed in GraphPad Prism version 9.4.1. Normality and lognormality
732 tests were performed for each dataset. All performed statistical tests were two sided. Mann–Whitney
733 U test was performed for unpaired nonparametric tests, and t tests or one-way analysis of variance
734 (ANOVA) followed by Dunnett's multiple comparisons test were performed for unpaired parametric
735 tests.

736

737

738 **References**

1. Keshavjee, S., and Farmer, P.E. (2012). Tuberculosis, drug resistance, and the history of modern medicine. *N Engl J Med* 367, 931-936. 10.1056/NEJMra1205429.
2. Gagneux, S. (2018). Ecology and evolution of *Mycobacterium tuberculosis*. *Nat Rev Microbiol* 16, 202-213. 10.1038/nrmicro.2018.8.
3. Warner, D.F., Rock, J.M., Fortune, S.M., and Mizrahi, V. (2017). DNA Replication Fidelity in the *Mycobacterium tuberculosis* Complex. *Adv Exp Med Biol* 1019, 247-262. 10.1007/978-3-319-64371-7_13.
4. McHenry, C.S. (2011). DNA replicases from a bacterial perspective. *Annu Rev Biochem* 80, 403-436. 10.1146/annurev-biochem-061208-091655.
5. Gygli, S.M., Borrell, S., Trauner, A., and Gagneux, S. (2017). Antimicrobial resistance in *Mycobacterium tuberculosis*: mechanistic and evolutionary perspectives. *FEMS Microbiol Rev* 41, 354-373. 10.1093/femsre/fux011.
6. Scheuermann, R., Tam, S., Burgers, P.M., Lu, C., and Echols, H. (1983). Identification of the epsilon-subunit of *Escherichia coli* DNA polymerase III holoenzyme as the dnaQ gene product: a fidelity subunit for DNA replication. *Proc Natl Acad Sci U S A* 80, 7085-7089. 10.1073/pnas.80.23.7085.
7. Tanabe, K., Kondo, T., Onodera, Y., and Furusawa, M. (1999). A conspicuous adaptability to antibiotics in the *Escherichia coli* mutator strain, dnaQ49. *FEMS Microbiol Lett* 176, 191-196. 10.1111/j.1574-6968.1999.tb13661.x.
8. Taft-Benz, S.A., and Schaaper, R.M. (1998). Mutational analysis of the 3'-->5' proofreading exonuclease of *Escherichia coli* DNA polymerase III. *Nucleic Acids Res* 26, 4005-4011. 10.1093/nar/26.17.4005.
9. Slater, S.C., Lifsics, M.R., O'Donnell, M., and Maurer, R. (1994). holE, the gene coding for the theta subunit of DNA polymerase III of *Escherichia coli*: characterization of a holE mutant and comparison with a dnaQ (epsilon-subunit) mutant. *J Bacteriol* 176, 815-821. 10.1128/jb.176.3.815-821.1994.
10. Studwell, P.S., and O'Donnell, M. (1990). Processive replication is contingent on the exonuclease subunit of DNA polymerase III holoenzyme. *J Biol Chem* 265, 1171-1178.
11. Rock, J.M., Lang, U.F., Chase, M.R., Ford, C.B., Gerrick, E.R., Gawande, R., Coscolla, M., Gagneux, S., Fortune, S.M., and Lamers, M.H. (2015). DNA replication fidelity in *Mycobacterium tuberculosis* is mediated by an ancestral prokaryotic proofreader. *Nat Genet* 47, 677-681. 10.1038/ng.3269.
12. Taddei, F., Radman, M., Maynard-Smith, J., Toupancre, B., Gouyon, P.H., and Godelle, B. (1997). Role of mutator alleles in adaptive evolution. *Nature* 387, 700-702. 10.1038/42696.
13. Timinskas, K., Balvociute, M., Timinskas, A., and Venclovas, C. (2014). Comprehensive analysis of DNA polymerase III alpha subunits and their homologs in bacterial genomes. *Nucleic Acids Res* 42, 1393-1413. 10.1093/nar/gkt900.
14. Stano, N.M., Chen, J., and McHenry, C.S. (2006). A coproofreading Zn(2+)-dependent exonuclease within a bacterial replicase. *Nat Struct Mol Biol* 13, 458-459. 10.1038/nsmb1078.
15. Ditse, Z., Lamers, M.H., and Warner, D.F. (2017). DNA Replication in *Mycobacterium tuberculosis*. *Microbiol Spectr* 5. 10.1128/microbiolspec.TB-TB2-0027-2016.

781 16. Lee, H., Popodi, E., Tang, H., and Foster, P.L. (2012). Rate and molecular spectrum of
782 spontaneous mutations in the bacterium *Escherichia coli* as determined by whole-genome
783 sequencing. *Proc Natl Acad Sci U S A* 109, E2774-2783. 10.1073/pnas.1210309109.

784 17. Foster, P.L. (2006). Methods for determining spontaneous mutation rates. *Methods Enzymol*
785 409, 195-213. 10.1016/S0076-6879(05)09012-9.

786 18. Kucukyildirim, S., Long, H., Sung, W., Miller, S.F., Doak, T.G., and Lynch, M. (2016). The
787 Rate and Spectrum of Spontaneous Mutations in *Mycobacterium smegmatis*, a Bacterium
788 Naturally Devoid of the Postreplicative Mismatch Repair Pathway. *G3 (Bethesda)* 6, 2157-
789 2163. 10.1534/g3.116.030130.

790 19. Kreutzer, D.A., and Essigmann, J.M. (1998). Oxidized, deaminated cytosines are a source
791 of C --> T transitions in vivo. *Proc Natl Acad Sci U S A* 95, 3578-3582.
792 10.1073/pnas.95.7.3578.

793 20. Wu, T.H., Clarke, C.H., and Marinus, M.G. (1990). Specificity of *Escherichia coli* mutD and
794 mutL mutator strains. *Gene* 87, 1-5. 10.1016/0378-1119(90)90488-d.

795 21. Bichara, M., Wagner, J., and Lambert, I.B. (2006). Mechanisms of tandem repeat instability
796 in bacteria. *Mutat Res* 598, 144-163. 10.1016/j.mrfmmm.2006.01.020.

797 22. Bellerose, M.M., Baek, S.H., Huang, C.C., Moss, C.E., Koh, E.I., Proulx, M.K., Smith, C.M.,
798 Baker, R.E., Lee, J.S., Eum, S., et al. (2019). Common Variants in the Glycerol Kinase Gene
799 Reduce Tuberculosis Drug Efficacy. *mBio* 10. 10.1128/mBio.00663-19.

800 23. Safi, H., Gopal, P., Lingaraju, S., Ma, S., Levine, C., Dartois, V., Yee, M., Li, L., Blanc, L., Ho
801 Liang, H.P., et al. (2019). Phase variation in *Mycobacterium tuberculosis* glpK produces
802 transiently heritable drug tolerance. *Proc Natl Acad Sci U S A* 116, 19665-19674.
803 10.1073/pnas.1907631116.

804 24. Vargas, R., Jr., Luna, M.J., Freschi, L., Marin, M., Froom, R., Murphy, K.C., Campbell, E.A.,
805 Ioerger, T.R., Sassetti, C.M., and Farhat, M.R. (2023). Phase variation as a major
806 mechanism of adaptation in *Mycobacterium tuberculosis* complex. *Proc Natl Acad Sci U S*
807 A 120, e2301394120. 10.1073/pnas.2301394120.

808 25. Dalrymple, B.P., Kongsuwan, K., Wijffels, G., Dixon, N.E., and Jennings, P.A. (2001). A
809 universal protein-protein interaction motif in the eubacterial DNA replication and repair
810 systems. *Proc Natl Acad Sci U S A* 98, 11627-11632. 10.1073/pnas.191384398.

811 26. Toste Rego, A., Holding, A.N., Kent, H., and Lamers, M.H. (2013). Architecture of the Pol III-
812 clamp-exonuclease complex reveals key roles of the exonuclease subunit in processive
813 DNA synthesis and repair. *EMBO J* 32, 1334-1343. 10.1038/emboj.2013.68.

814 27. Errol C. Friedberg, G.C.W., Wolfram Siede, Richard D. Wood, Roger A. Schultz, Tom
815 Ellenberger. (2005). *DNA Repair and Mutagenesis*, Second Edition (ASM Press).

816 28. Adefisayo, O.O., Dupuy, P., Nautiyal, A., Bean, J.M., and Glickman, M.S. (2021). Division of
817 labor between SOS and PafBC in mycobacterial DNA repair and mutagenesis. *Nucleic Acids*
818 *Res* 49, 12805-12819. 10.1093/nar/gkab1169.

819 29. Wendel, B.M., Cole, J.M., Courcelle, C.T., and Courcelle, J. (2018). SbcC-SbcD and Exol
820 process convergent forks to complete chromosome replication. *Proc Natl Acad Sci U S A*
821 115, 349-354. 10.1073/pnas.1715960114.

822 30. Sinha, K.M., Unciuleac, M.C., Glickman, M.S., and Shuman, S. (2009). AdnAB: a new DSB-
823 resecting motor-nuclease from mycobacteria. *Genes Dev* 23, 1423-1437.
824 10.1101/gad.1805709.

825 31. Michel, B., Grompone, G., Flores, M.J., and Bidnenko, V. (2004). Multiple pathways process
826 stalled replication forks. *Proc Natl Acad Sci U S A* 101, 12783-12788.
827 10.1073/pnas.0401586101.

828 32. Heller, R.C., and Marians, K.J. (2006). Replisome assembly and the direct restart of stalled
829 replication forks. *Nat Rev Mol Cell Biol* 7, 932-943. 10.1038/nrm2058.

830 33. Maki, H., Horiuchi, T., and Sekiguchi, M. (1983). Isolation of conditional lethal mutator
831 mutants of *Escherichia coli* by localized mutagenesis. *J Bacteriol* 153, 1361-1367.
832 10.1128/jb.153.3.1361-1367.1983.

833 34. Pohlhaus, J.R., Long, D.T., O'Reilly, E., and Kreuzer, K.N. (2008). The epsilon subunit of
834 DNA polymerase III Is involved in the nalidixic acid-induced SOS response in *Escherichia*
835 *coli*. *J Bacteriol* 190, 5239-5247. 10.1128/JB.00173-08.

836 35. Mustaev, A., Malik, M., Zhao, X., Kurepina, N., Luan, G., Oppegard, L.M., Hiasa, H., Marks,
837 K.R., Kerns, R.J., Berger, J.M., and Drlica, K. (2014). Fluoroquinolone-gyrase-DNA
838 complexes: two modes of drug binding. *J Biol Chem* 289, 12300-12312.
839 10.1074/jbc.M113.529164.

840 36. Aldred, K.J., McPherson, S.A., Turnbough, C.L., Jr., Kerns, R.J., and Osheroff, N. (2013).
841 Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge:
842 mechanistic basis of quinolone resistance. *Nucleic Acids Res* 41, 4628-4639.
843 10.1093/nar/gkt124.

844 37. Grompone, G., Ehrlich, S.D., and Michel, B. (2003). Replication restart in *gyrB* *Escherichia*
845 *coli* mutants. *Mol Microbiol* 48, 845-854. 10.1046/j.1365-2958.2003.03480.x.

846 38. Khodursky, A.B., Peter, B.J., Schmid, M.B., DeRisi, J., Botstein, D., Brown, P.O., and
847 Cozzarelli, N.R. (2000). Analysis of topoisomerase function in bacterial replication fork
848 movement: use of DNA microarrays. *Proc Natl Acad Sci U S A* 97, 9419-9424.
849 10.1073/pnas.97.17.9419.

850 39. Ojkic, N., Lilja, E., Direito, S., Dawson, A., Allen, R.J., and Waclaw, B. (2020). A Roadblock-
851 and-Kill Mechanism of Action Model for the DNA-Targeting Antibiotic Ciprofloxacin.
852 *Antimicrob Agents Chemother* 64. 10.1128/AAC.02487-19.

853 40. Liu, Q., Zhu, J., Dulberger, C.L., Stanley, S., Wilson, S., Chung, E.S., Wang, X., Culviner,
854 P., Liu, Y.J., Hicks, N.D., et al. (2022). Tuberculosis treatment failure associated with
855 evolution of antibiotic resilience. *Science* 378, 1111-1118. 10.1126/science.abq2787.

856 41. Stucki, D., Brites, D., Jeljeli, L., Coscolla, M., Liu, Q., Trauner, A., Fenner, L., Rutaihwa, L.,
857 Borrell, S., Luo, T., et al. (2016). *Mycobacterium tuberculosis* lineage 4 comprises globally
858 distributed and geographically restricted sublineages. *Nat Genet* 48, 1535-1543.
859 10.1038/ng.3704.

860 42. Whatley, Z., and Kreuzer, K.N. (2015). Mutations that Separate the Functions of the
861 Proofreading Subunit of the *Escherichia coli* Replicase. *G3 (Bethesda)* 5, 1301-1311.
862 10.1534/g3.115.017285.

863 43. Hamdan, S., Carr, P.D., Brown, S.E., Ollis, D.L., and Dixon, N.E. (2002). Structural basis for
864 proofreading during replication of the *Escherichia coli* chromosome. *Structure* 10, 535-546.
865 10.1016/s0969-2126(02)00738-4.

866 44. LeClerc, J.E., Li, B., Payne, W.L., and Cebula, T.A. (1996). High mutation frequencies
867 among *Escherichia coli* and *Salmonella* pathogens. *Science* 274, 1208-1211.
868 10.1126/science.274.5290.1208.

869 45. Oliver, A., Canton, R., Campo, P., Baquero, F., and Blazquez, J. (2000). High frequency of
870 hypermutable *Pseudomonas aeruginosa* in cystic fibrosis lung infection. *Science* 288, 1251-
871 1254. 10.1126/science.288.5469.1251.

872 46. Ford, C.B., Shah, R.R., Maeda, M.K., Gagneux, S., Murray, M.B., Cohen, T., Johnston, J.C.,
873 Gardy, J., Lipsitch, M., and Fortune, S.M. (2013). *Mycobacterium tuberculosis* mutation rate
874 estimates from different lineages predict substantial differences in the emergence of drug-
875 resistant tuberculosis. *Nat Genet* 45, 784-790. 10.1038/ng.2656.

876 47. Walker, T.M., Miotto, P., Koser, C.U., Fowler, P.W., Knaggs, J., Iqbal, Z., Hunt, M.,
877 Chindelevitch, L., Farhat, M., Cirillo, D.M., et al. (2022). The 2021 WHO catalogue of
878 *Mycobacterium tuberculosis* complex mutations associated with drug resistance: A
879 genotypic analysis. *Lancet Microbe* 3, e265-e273. 10.1016/S2666-5247(21)00301-3.

880 48. Wing, R.A., Bailey, S., and Steitz, T.A. (2008). Insights into the replisome from the structure
881 of a ternary complex of the DNA polymerase III alpha-subunit. *J Mol Biol* 382, 859-869.
882 10.1016/j.jmb.2008.07.058.

883 49. Barros, T., Guenther, J., Kelch, B., Anaya, J., Prabhakar, A., O'Donnell, M., Kuriyan, J., and
884 Lamers, M.H. (2013). A structural role for the PHP domain in *E. coli* DNA polymerase III.
885 *BMC Struct Biol* 13, 8. 10.1186/1472-6807-13-8.

886 50. Malshetty, V.S., Jain, R., Srinath, T., Kurthkoti, K., and Varshney, U. (2010). Synergistic
887 effects of UdgB and Ung in mutation prevention and protection against commonly
888 encountered DNA damaging agents in *Mycobacterium smegmatis*. *Microbiology (Reading)*
889 156, 940-949. 10.1099/mic.0.034363-0.

890 51. Dupuy, P., Howlader, M., and Glickman, M.S. (2020). A multilayered repair system protects
891 the mycobacterial chromosome from endogenous and antibiotic-induced oxidative damage.
892 *Proc Natl Acad Sci U S A* 117, 19517-19527. 10.1073/pnas.2006792117.

893 52. Lind, P.A., and Andersson, D.I. (2008). Whole-genome mutational biases in bacteria. *Proc
894 Natl Acad Sci U S A* 105, 17878-17883. 10.1073/pnas.0804445105.

895 53. Johnson, S.J., and Beese, L.S. (2004). Structures of mismatch replication errors observed
896 in a DNA polymerase. *Cell* 116, 803-816. 10.1016/s0092-8674(04)00252-1.

897 54. Reha-Krantz, L.J. (2010). DNA polymerase proofreading: Multiple roles maintain genome
898 stability. *Biochim Biophys Acta* 1804, 1049-1063. 10.1016/j.bbapap.2009.06.012.

899 55. Fernandez-Leiro, R., Conrad, J., Yang, J.C., Freund, S.M., Scheres, S.H., and Lamers, M.H.
900 (2017). Self-correcting mismatches during high-fidelity DNA replication. *Nat Struct Mol Biol*
901 24, 140-143. 10.1038/nsmb.3348.

902 56. Jolly, S.M., Gainetdinov, I., Jouravleva, K., Zhang, H., Strittmatter, L., Bailey, S.M.,
903 Hendricks, G.M., Dhabaria, A., Ueberheide, B., and Zamore, P.D. (2020). *Thermus
904 thermophilus* Argonaute Functions in the Completion of DNA Replication. *Cell* 182, 1545-
905 1559 e1518. 10.1016/j.cell.2020.07.036.

906 57. Guo, M.S., Haakonsen, D.L., Zeng, W., Schumacher, M.A., and Laub, M.T. (2018). A
907 Bacterial Chromosome Structuring Protein Binds Overtwisted DNA to Stimulate Type II
908 Topoisomerases and Enable DNA Replication. *Cell* 175, 583-597 e523.
909 10.1016/j.cell.2018.08.029.

910 58. Schaaper, R.M., and Cornacchio, R. (1992). An *Escherichia coli* dnaE mutation with
911 suppressor activity toward mutator mutD5. *J Bacteriol* 174, 1974-1982.
912 10.1128/jb.174.6.1974-1982.1992.

913 59. Lancy, E.D., Lifsics, M.R., Kehres, D.G., and Maurer, R. (1989). Isolation and
914 characterization of mutants with deletions in dnaQ, the gene for the editing subunit of DNA
915 polymerase III in *Salmonella typhimurium*. *J Bacteriol* 171, 5572-5580.
916 10.1128/jb.171.10.5572-5580.1989.

917 60. Boshoff, H.I., Reed, M.B., Barry, C.E., 3rd, and Mizrahi, V. (2003). DnaE2 polymerase
918 contributes to in vivo survival and the emergence of drug resistance in *Mycobacterium*
919 *tuberculosis*. *Cell* 113, 183-193. 10.1016/s0092-8674(03)00270-8.

920 61. Snapper, S.B., Melton, R.E., Mustafa, S., Kieser, T., and Jacobs, W.R., Jr. (1990). Isolation
921 and characterization of efficient plasmid transformation mutants of *Mycobacterium*
922 *smegmatis*. *Mol Microbiol* 4, 1911-1919. 10.1111/j.1365-2958.1990.tb02040.x.

923 62. Bardarov, S., Bardarov, S., Pavelka, M.S., Sambandamurthy, V., Larsen, M., Tufariello, J.,
924 Chan, J., Hatfull, G., and Jacobs, W.R. (2002). Specialized transduction: an efficient method
925 for generating marked and unmarked targeted gene disruptions in *Mycobacterium*
926 *tuberculosis*, *M. bovis* BCG and *M. smegmatis*. *Microbiology (Reading)* 148, 3007-3017.
927 10.1099/00221287-148-10-3007.

928 63. Williams, K.J., Joyce, G., and Robertson, B.D. (2010). Improved mycobacterial tetracycline
929 inducible vectors. *Plasmid* 64, 69-73. 10.1016/j.plasmid.2010.04.003.

930 64. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella,
931 K., Altshuler, D., Gabriel, S., Daly, M., and DePristo, M.A. (2010). The Genome Analysis
932 Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.
933 *Genome Res* 20, 1297-1303. 10.1101/gr.107524.110.

934 65. Hall, B.M., Ma, C.X., Liang, P., and Singh, K.K. (2009). Fluctuation analysis CalculatOR: a
935 web tool for the determination of mutation rate using Luria-Delbrück fluctuation analysis.
936 *Bioinformatics* 25, 1564-1565. 10.1093/bioinformatics/btp253.

937 66. Sarkar, S., Ma, W.T., and Sandri, G.H. (1992). On fluctuation analysis: a new, simple and
938 efficient method for computing the expected number of mutants. *Genetica* 85, 173-179.
939 10.1007/BF00120324.

940 67. Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina
941 sequence data. *Bioinformatics* 30, 2114-2120. 10.1093/bioinformatics/btu170.

942 68. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat
943 Methods* 9, 357-359. 10.1038/nmeth.1923.

944 69. Wang, L., Feng, Z., Wang, X., Wang, X., and Zhang, X. (2010). DEGseq: an R package for
945 identifying differentially expressed genes from RNA-seq data. *Bioinformatics* 26, 136-138.
946 10.1093/bioinformatics/btp612.

947 70. Widdel, F. (2007). Theory and measurement of bacterial growth. Di Dalam *Grundpraktikum
948 Mikrobiologie* 4, 1-11.

949 71. Joshi, N., and Fass, J. (2011). Sickle: A sliding-window, adaptive, quality-based trimming
950 tool for FastQ files (Version 1.33)[Software].

951 72. Comas, I., Coscolla, M., Luo, T., Borrell, S., Holt, K.E., Kato-Maeda, M., Parkhill, J., Malla,
952 B., Berg, S., Thwaites, G., et al. (2013). Out-of-Africa migration and Neolithic coexpansion
953 of *Mycobacterium tuberculosis* with modern humans. *Nature genetics* 45, 1176-1182.
954 10.1038/ng.2744.

955 73. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G.,
956 Durbin, R., and Genome Project Data Processing, S. (2009). The Sequence Alignment/Map

957 format and SAMtools. *Bioinformatics* 25, 2078-2079. 10.1093/bioinformatics/btp352.

958 74. Marin, M., Vargas, R., Harris, M., Jeffrey, B., Epperson, L.E., Durbin, D., Strong, M.,
959 Salfinger, M., Iqbal, Z., Akhundova, I., et al. (2022). Benchmarking the empirical accuracy
960 of short-read sequencing across the *M. tuberculosis* genome. *Bioinformatics*.
961 10.1093/bioinformatics/btac023.

962 75. Coll, F., McNerney, R., Guerra-Assuncao, J.A., Glynn, J.R., Perdigao, J., Viveiros, M.,
963 Portugal, I., Pain, A., Martin, N., and Clark, T.G. (2014). A robust SNP barcode for typing
964 *Mycobacterium tuberculosis* complex strains. *Nature communications* 5, 4812.
965 10.1038/ncomms5812.

966 76. Liu, Q., Ma, A., Wei, L., Pang, Y., Wu, B., Luo, T., Zhou, Y., Zheng, H.X., Jiang, Q., Gan, M.,
967 et al. (2018). China's tuberculosis epidemic stems from historical expansion of four strains
968 of *Mycobacterium tuberculosis*. *Nat Ecol Evol* 2, 1982-1992. 10.1038/s41559-018-0680-6.

969 77. Trauner, A., Liu, Q., Via, L.E., Liu, X., Ruan, X., Liang, L., Shi, H., Chen, Y., Wang, Z., Liang,
970 R., et al. (2017). The within-host population dynamics of *Mycobacterium tuberculosis* vary
971 with treatment efficacy. *Genome Biol* 18, 71. 10.1186/s13059-017-1196-0.

972

973

974 **Table 1**


975 **Deletion of *dnaQ* results in a mutator phenotype in mutation accumulation assay**

Strain	No. of BPSs	No. of indels	No. of lines	Generations per line	Total No. of generations	Mutation rate per base pair \pm 95% CI ($\times 10^{-10}$)	Mutation rate per genome \pm 95% CI ($\times 10^{-3}$)
WT	23	10	12	815	9780	4.88 \pm 1.90	3.39 \pm 1.29
Δ <i>dnaQ</i>	50	16	10	815	8150	11.68 \pm 4.63	8.08 \pm 3.14
Δ <i>Ms4259</i>	32	7	10	815	8150	6.83 \pm 1.95	4.78 \pm 1.40
Δ <i>Ms4259</i> Δ <i>dnaQ</i>	44	11	12	930	11160	7.09 \pm 2.36	4.94 \pm 1.62

976 Mutation rates were estimated by mutant accumulation assay. Mutations are classified according to
977 base-pair substitutions (BPSs) or indels (defined here as insertions or deletions of \leq 30 nucleotides).
978 CI, confidence intervals.

979


980



981

982 **Figure 1. Deletion of *dnaQ* in *Msm* results in a mutational bias for AT and increased**
983 **insertions/deletions in homopolymeric tract.**


984 (A) Fluctuation analysis in *Msm* strains. *dnaQ* Exo⁻, DnaQ[D28A/E30A/D112A] variant deficient in
985 exonuclease activity; H37Rv_ *dnaQ*, *dnaQ* allele from *Mtb* strain H37Rv. Circles represent mutant
986 frequency (number of rifampicin-resistant mutants per cell plated). Estimated mutation rates
987 (mutations conferring rifampicin resistance per generation) were shown as mean \pm 95% CI.
988 Significance was determined using a one-way analysis of variance test on log transformed values;
989 *P < 0.05, **P < 0.01, ***P < 0.0001.
990 (B-D) Mutational spectra identified from the MA assay. (B) Mutation rates of each of the BPS
991 mutational spectra. (C) Mutation rates of the A/T>GC and G/C>AT events normalized to the genomic
992 AT and GC content, respectively. (D) Mutation rates of the indel events occurred in homopolymeric
993 tract. Data shown are mean \pm 95% CI. *P < 0.05, **P < 0.01, ***P < 0.001 by the Mann-Whitney U test
994 compared to the counterpart of WT.



995

Figure 2. Mycobacterial DnaQ specifically corrects errors produced during DNA replication.

996 (A) Fluctuation analysis in *Msm* strains expressing of wild-type *dnaE1* or allele encoding a mutant
997 deficient in PHP-mediated proofreading activity (*dnaE1[D228N]*). Circles represent mutant
998 frequency. Estimated mutation rates (mutations conferring rifampicin resistance per generation)
999 were shown as mean \pm 95% CI. Significance was determined by comparing strain pairs using an
1000 unpaired t test on log transformed values; * $P < 0.05$, *** $P < 0.001$.
1001 (B) Immunoprecipitation eluates analyzed by silver staining. Immunoprecipitation experiments were
1002 performed with FLAG antibody in the Δ *dnAQ* mutant strain expressing either wild-type *dnaQ* (DnaQ)
1003 or alleles encoding DnaQ containing a FLAG tag at C terminal (DnaQ_C-FLAG) or N terminal
1004 (DnaQ_N-FLAG). Precipitated DnaQ and DnaN were identified by LC-MS/MS.
1005 (C) Peptide coverage of the precipitated proteins identified by LC-MS/MS.
1006 (D) Sequences of the clamp-binding motif (CBM) identified in mycobacterial DnaQ, DnaE1, NucS,
1007 and *E. coli* (Ec) DnaQ. Numbers indicate the peptide position.
1008 (E) Pull-down eluates analyzed by Coomassie blue staining. DnaQ_Trx_His6, DnaQ fused with a N-
1009 terminal Trx domain containing 6 \times His tag; DnaQ_Cdel_Trx_His6, DnaQ_Trx_His6 with deletion of C-
1010 terminal CBM. DnaN, native DnaN without His tag.
1011 (F) DnaQ 3'-5' exonuclease activity on single-strand DNA (ssDNA). Reactions were performed with
1012 a 24nt FAM-labeled ssDNA for 5 minutes.
1013 (G) Rif^R mutation frequencies of the indicated strains exposed to 5mM H₂O₂ or 25mJ/cm² UV. Data
1014 shown are mean \pm 95% CI.



1016

1017 **Figure 3. DnaQ deficiency results in replication fork perturbation and affects DNA replication**
1018 **fidility upon topological stress.**

1019 (A-C) transcriptional profiling of WT and the mutant strains deficient in DnaQ or DnaQ homolog
1020 encoded by *Ms4259*.

1021 (A) DnaQ-depleted cells induce a DNA damage response (DDR), DDR genes were categorized
1022 according to the established mycobacterial DDR regulons (PafBC/SOS regulon, PafBC regulon and
1023 unknonwn).

1024 (B) Enrichment analyses of the differential expressed genes in the DnaQ-depleted cells according
1025 to three DDR regulons.


1026 (C) Differential expressed PafBC regulon genes in indicated strains. End, endonuclease.

1027 (D) Growth of the indicated strains assessed by 10-fold serial dilutions on 7H10 plates with or without
1028 sub-MIC Ofx.

1029 (E) Growth rate of the indicated strains in the presence of sub-MIC of Ofx. Bacterial growth was
1030 measure by OD₆₀₀, growth rate was calculated from exponential-phase of growth (OD₆₀₀ within
1031 0.1~0.4) and expressed relative to the untreated counterparts. Data shown are mean ± 95% CI.
1032 *P<0.05, **P<0.01 using an unpaired t test compared to WT.

1033 (F) Rif^R mutation frequencies of the indicated strains after exposure to Ofx. Data shown are mean ±
1034 95% CI. * $P<0.05$, ** $P<0.01$ using an unpaired t test on log transformed values.
1035

1036



1037

1038 **Figure 4. A *DnaQ*[V88A] variant prevalent in *Mtb* L4.3 sublineage confers hypermutability and**

1039 associates with drug resistance.


1040 (A) A representative phylogenetic tree highlighting the stepwise mutations of *dnaQ* in *Mtb* lineages.

1041 (B) A phylogenetic tree of L4.3 with the mutational events of *dnaQ* marked. * refers to a pre-stop

1042 mutation.

1043 (C) Comparison of SNP numbers among *Mtb* strains within sublineage L4.3. “WT-neighbor” refer to
1044 the closest phylogenetic clades that are neighboring to *dnaQ* V88A or *dnaQ* G151R clades.
1045 (D-E) Fluctuation analyses in *Msm* Δ *dnaQ* mutant (D) or the *Mtb* Δ *dnaQ* mutant (E) expressing of a
1046 variety of *dnaQ* alleles identified in clinical *Mtb*. Circles represent mutant frequency. Estimated
1047 mutation rates were shown as mean \pm 95% CI. **** P <0.0001, using a one-way analysis of variance
1048 test on log transformed values compared with ancestral-type (D) or H37Rv WT (E).
1049 (F) The number of drug-resistant (DR) mutational events identified in each *Mtb* isolate containing
1050 *DnaQ* A88 or V88 (A88 neighbor). n indicates the number of drug resistant *Mtb* isolates. Significance
1051 was analyzed using a Mann–Whitney U test.
1052 (G) Proportion of drug resistance to individual anti-tuberculosis drug. INH, isoniazid; RIF, rifampicin;
1053 EMB, ethambutol; PZA, pyrazinamide; STM, streptomycin; ETH, ethionamide; KAN, kanamycin;
1054 LEV, levofloxacin; MXF, moxifloxacin; AMI, amikacin; CAP, capreomycin. Significance was analyzed
1055 using a Chi-square test.
1056 (H) Drug resistance profiles of *Mtb* isolates containing *DnaQ* A88 or V88 (A88 neighbor) in Peru, UK,
1057 and all countries (ALL). The numbers of *Mtb* isolates were indicated above the column. DS, drug
1058 sensitive. DR#, the number of drugs being resistant.

1059



1060

1061 **Figure 5. Proposed action model of DnaQ in *Mycobacteria*.**

1062 (A) A schematic view of the architecture of the replisome between *Mycobacteria* and *E. coli*. The ψ
1063 and χ subunit are not shown. Compared with the *E. coli* model, the mycobacterial replisome has
1064 three distinct characters, 1) contains two proofreaders (PHP and ϵ subunit), 2) the ϵ subunit may
1065 not form a stable complex with the α subunit, and 3) contains an active PHP exonuclease domain.
1066 (B-C) Mycobacterial DnaQ participates in maintenance of genomic GC content (B) and sustaining
1067 of DNA replication fidelity upon chromosomal topological stress (C). See also *Discussion*.
1068 (D) Possible mechanisms of DnaQ[V88A]'s effect on mutagenesis.